Navigation Links
Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
Date:5/10/2013

d drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, characterizations of the results of and projected timing of clinical trials, and the potential therapeutic and commercial potential of LX4211.  This press release also contains forward-looking statements regarding Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to upd
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014  Depomed, Inc. (NASDAQ: DEPO ) ... year 2014 financial results after the market closes on Wednesday, ... call beginning at 4:30 pm EDT, 1:30 pm PDT to discuss ... by dialing 877-317-6789 ( United States ) ... available via a live webcast on the investor relations ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... Powers Lake, Wisconsin , announce ... distribution and co-marketing agreement allowing ScriptPro to bring ... the United States . ScriptPro ... and workflow systems to retail and ambulatory pharmacies. ...
(Date:7/25/2014)... -- CVS Caremark Corporation (NYSE: CVS ) will ... 2014, at 8:30 a.m. (EDT) with analysts and investors ... An audio webcast of the conference call will ... the CVS Caremark website for all interested parties.  To ... will be archived and available on the web site ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3
... Mylan Inc. (Nasdaq: www.mylan.com . ... release includes statements that constitute "forward-looking statements." These statements ... the Private Securities Litigation Reform Act of 1995. Because ... results may differ materially from those expressed or implied ...
... 6 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... Specialty Pharmaceuticals Conference on Thursday, August 12, 2010 , at 8:00 ... Endo, will review the company,s products and development programs. , ... The presentation will be webcast live and can ...
Cached Medicine Technology:Endo to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference 2
(Date:7/25/2014)... The Little Gym of Houston will attend the ... at Discovery Green in downtown Houston. The eleven ... Spring, The Woodlands, Sugarland-Missouri City, Kingwood, Bellaire and their ... to be attending and performing at the Family Fun ... Sugarland-Missouri City location. “We believe in the message and ...
(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... California Memorial Stadium. With the post-World Cup emotions still rolling ... the 2014 Guinness International Champions Cup have brought eight of ... representing La Liga, English Premier League, Serie A, and Superleague ... players from around the world to 12 American cities and ...
(Date:7/25/2014)... AZ (PRWEB) July 25, 2014 ... , a Nuanced Media client and the nation’s ... and dental employee handbooks, announced their partnership with ... TransAct is a registered ISO/MSP of Chase Paymentech ... the transaction processing industry. Companies that are members ...
(Date:7/25/2014)... 25, 2014 Hastings and Hastings, ... attorney’s fees with regard to personal injury claims, announces ... wide range of legal services for those that have ... another individual or corporation. Free initial consultation services gives ... of a potential personal injury claim . It ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
... May 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... of pharmaceutical, medicinal and diagnostic products in China,today ... at 5:00 p.m. Eastern,Time on May 15, 2008 ... Joining Mr. Yan-qing Liu, Chairman, CEO and ...
... blood-pressure drugs given in the study were probably too high ... the blood pressure-lowering drugs known as beta blockers after having ... a stroke, a new Canadian study found. , However, the ... heart attack, according to the report in the May 13 ...
... 13 Paramed Systems today announced,the release and first ... fully motorized stair climbing chair to oil and,gas platform ... the MOV chair on,drilling platforms will enable the safe ... platform., Paramed developed the dual-track MOV in response ...
... Calif., May 13 TorreyPines Therapeutics, Inc.,(Nasdaq: TPTX ... first quarter ended March 31, 2008. For the three-month ... net loss of $3.9 million. Cash,and cash equivalents totaled ... been diligently executing on the strategic plan outlined in,February, ...
... Calif., May 13 Visage Imaging,Inc., a wholly ... announced it was selected by Tufts Medical Center, ... system with the fully integrated,Visage Cardiac Analysis Package. ... offering outstanding patient care, teaching,generations of future physicians ...
... platform updates and product road map for developers., ... take the next step toward increasing patient safety ... Microsoft Health Common User,Interface (CUI), available today from ... toolkit controls and showcase demonstrators,the Microsoft Health CUI ...
Cached Medicine News:Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Beta Blockers Raise Stroke, Death Risk After Surgery 2Health News:Beta Blockers Raise Stroke, Death Risk After Surgery 3Health News:TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 2Health News:TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 3Health News:TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 4Health News:TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 5Health News:TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 6Health News:TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 7Health News:Visage Imaging to Provide Fully Integrated Thin Client-Based Solution to Tufts Medical Center 2Health News:Visage Imaging to Provide Fully Integrated Thin Client-Based Solution to Tufts Medical Center 3Health News:Updated Microsoft Health Common User Interface Furthers Clinical Effectiveness, Increases Patient Safety 2Health News:Updated Microsoft Health Common User Interface Furthers Clinical Effectiveness, Increases Patient Safety 3
... breakthrough continuous low-flow nebulizer performance. Patented ... technology allows for optimal medication and ... Heliox). OMNI~NEB takes on severe asthma, ... and critical care situations. Configure with ...
... developing diverse medical products for ... medical-surgical products have earned an ... and customer satisfaction. Graham-Fields internationally ... line of diagnostic instruments, Grafco® ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
Medicine Products: